{"id":904628,"date":"2025-11-03T18:20:59","date_gmt":"2025-11-03T23:20:59","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-to-participate-in-the-stifel-2025-healthcare-conference\/"},"modified":"2025-11-03T18:20:59","modified_gmt":"2025-11-03T23:20:59","slug":"nyxoah-to-participate-in-the-stifel-2025-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nyxoah-to-participate-in-the-stifel-2025-healthcare-conference\/","title":{"rendered":"Nyxoah to Participate in the Stifel 2025 Healthcare Conference"},"content":{"rendered":"
\n

\n Nyxoah to Participate in the Stifel 2025 Healthcare Conference<\/strong>\n <\/p>\n

\n Mont-Saint-Guibert, Belgium \u2013 November 3, 10:05pm CET \/ 4:05pm ET \u2013 Nyxoah SA (Euronext Brussels\/Nasdaq: NYXH)<\/strong>, a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Stifel 2025 Healthcare Conference on Tuesday, Nov. 11, 2025. The Company is scheduled to present at 9:20am Eastern Time the same day via webcast.<\/p>\n

A live webcast of the event can be accessed by visiting Nyxoah\u2019s Investor Relations website and will be available for replay following the events. The Company will also be available for 1×1 meetings with institutional investors attending the event.<\/p>\n

\n About Nyxoah<\/strong>\n <\/p>\n

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah\u2019s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world\u2019s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.<\/p>\n

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors\u2019 therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and U.S. FDA approval of a Premarket Approval application.<\/p>\n

\n Caution <\/strong>\u2013 CE marked since 2019. FDA approved in August 2025 as prescription-only device.<\/p>\n

\n FORWARD-LOOKING STATEMENTS<\/strong>\n <\/p>\n

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company\u2019s or, as appropriate, the Company directors\u2019 or managements\u2019 current expectations regarding the Genio system; planned and ongoing clinical studies of the Genio system; the potential advantages of the Genio system; Nyxoah\u2019s goals with respect to the development, regulatory pathway and potential use of the Genio system; the Company’s commercialization strategy and entrance to the U.S. market; the Company\u2019s intellectual property portfolio; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the \u201cRisk Factors\u201d section of the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (\u201cSEC\u201d) on March 20, 2025, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, or adverse litigation outcomes can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.<\/p>\n

\n Investor and Media Contact:<\/strong>\n <\/p>\n

R\u00e9mi Renard<\/p>\n

Chief Investor Relations and Corporate Communication Officer<\/p>\n

\n IR@nyxoah.com<\/a>\n <\/p>\n

\n Attachment<\/strong>\n <\/p>\n